title: Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report.
abstract: To date, there has been a lack of pediatric experience regarding the efficacy and tolerability of immune checkpoint inhibitors after haploidentical hematopoietic stem cell transplant (HSCT). We present the case of a 22-year-old female with multiple-relapsed Hodgkin lymphoma (HL) who presented with a new relapse after haploidentical (post-haplo) HSCT. Anti-PD-1 therapy with nivolumab resulted in significant objective disease response and clinical improvement without notable side effects, including the absence of a graft-versus-host disease (GVHD). This case report suggests that immune checkpoint inhibition may be safely tolerated even in the setting of haploidentical HSCT, without triggering overt GVHD.
authors.affiliation: Department of Pediatric Hematology/Oncology, The Herman & Walter Samuelson Children's Hospital at Sinai, Baltimore, Maryland.|Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.
authors.forename: Aziza T
authors.initials: AT
authors.lastname: Shad
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Huo
authors.affiliation: Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.
authors.forename: Courtney
authors.initials: C
authors.lastname: Darcy
authors.affiliation: Department of Pediatric Oncology, Medstar Georgetown University Hospital, Washington, District of Columbia.
authors.forename: Amal
authors.initials: A
authors.lastname: Abu-Ghosh
authors.affiliation: Department of Nuclear Medicine, Medstar Georgetown University Hospital, Washington, District of Columbia.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Esposito
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Mary-Jo
authors.initials: MJ
authors.lastname: Holuba
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Nancy
authors.initials: N
authors.lastname: Robey
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Cooke
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Symons
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Allen R
authors.initials: AR
authors.lastname: Chen
authors.affiliation: Department of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: Nicolas J
authors.initials: NJ
authors.lastname: Llosa
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D008212:Lymphocyte Depletion; D000077594:Nivolumab; D011379:Prognosis; D013601:T-Lymphocytes / Q000187:drug effects*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab
keywords: Hodgkin lymphoma; anti-PD1; haploidentical bone marrow transplant; immunotherapy; nivolumab; relapse